ALKS Latest Press Releases

-- October 30, 2026 --

Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD) Business Wire 7:00 AM

-- October 20, 2026 --

Alkermes to Report Third Quarter Financial Results on November 3, 2026 Business Wire 4:00 PM

-- October 13, 2026 --

Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research Business Wire 7:00 AM

-- September 21, 2026 --

Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD) Business Wire 7:00 AM

-- September 16, 2026 --

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors Business Wire 7:00 AM

-- September 10, 2026 --

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards Program Business Wire 7:00 AM

-- September 9, 2026 --

Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors Business Wire 8:00 AM

-- August 24, 2026 --

The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1 Business Wire 6:30 PM

-- July 28, 2026 --

Alkermes plc Reports Second Quarter 2026 Financial Results Business Wire 7:00 AM

-- July 14, 2026 --

Alkermes to Report Second Quarter Financial Results on July 28, 2026 Business Wire 4:00 PM

-- July 13, 2026 --

Alkermes' Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis Business Wire 7:00 AM

-- June 17, 2026 --

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026 Business Wire 4:15 PM

-- June 15, 2026 --

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe Business Wire 7:00 AM

-- June 4, 2026 --

Alkermes to Present New Data on Alixorexton and LUMRYZ (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research Business Wire 7:00 AM

-- June 3, 2026 --

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference Business Wire 4:05 PM

Market Data Delayed 15 Minutes